TARSUS PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
TARSUS PHARMACEUTICALS, INC. (TARS) reported Amortization of Debt Issuance Costs of $165.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $165.00K, a 13.01% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $159.00K, a 14.39% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $156.00K, a 13.04% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $152.00K, a 17.83% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2025 was $593.00K, a 47.51% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2024 was $402.00K, a 232.23% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2023 was $121.00K, a 10.37% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2022 was $135.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $165.00K 10-Q · filed 2026-08-06 | $325.00K 10-Q · filed 2026-08-06 | $480.00K derived: sum of 3 quarters · filed 2026-08-06 | $632.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $159.00K 10-Q · filed 2026-05-06 | $315.00K derived: sum of 2 quarters · filed 2026-05-06 | $467.00K derived: sum of 3 quarters · filed 2026-05-06 | $613.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $308.00K derived: sum of 2 quarters · filed 2026-02-23 | $454.00K derived: sum of 3 quarters · filed 2026-08-06 | $593.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $152.00K 10-Q · filed 2025-11-04 | $298.00K derived: sum of 2 quarters · filed 2026-08-06 | $437.00K 10-Q · filed 2025-11-04 | $575.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $146.00K 10-Q · filed 2026-08-06 | $285.00K 10-Q · filed 2026-08-06 | $423.00K derived: sum of 3 quarters · filed 2026-08-06 | $552.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $139.00K 10-Q · filed 2026-05-06 | $277.00K derived: sum of 2 quarters · filed 2026-05-06 | $406.00K derived: sum of 3 quarters · filed 2026-05-06 | $507.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $267.00K derived: sum of 2 quarters · filed 2026-02-23 | $368.00K derived: sum of 3 quarters · filed 2026-02-23 | $402.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $129.00K 10-Q · filed 2025-11-04 | $230.00K derived: sum of 2 quarters · filed 2025-11-04 | $264.00K 10-Q · filed 2025-11-04 | $295.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $101.00K 10-Q · filed 2025-08-06 | $135.00K 10-Q · filed 2025-08-06 | $166.00K derived: sum of 3 quarters · filed 2026-02-23 | $199.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $34.00K 10-Q · filed 2025-05-01 | $65.00K derived: sum of 2 quarters · filed 2026-02-23 | $98.00K derived: sum of 3 quarters · filed 2026-02-23 | $126.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $64.00K derived: sum of 2 quarters · filed 2026-02-23 | $92.00K derived: sum of 3 quarters · filed 2026-02-23 | $121.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-13 | $61.00K derived: sum of 2 quarters · filed 2024-11-13 | $90.00K 10-Q · filed 2024-11-13 | $120.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $28.00K 10-Q · filed 2024-08-08 | $57.00K 10-Q · filed 2024-08-08 | $87.00K derived: sum of 3 quarters · filed 2025-02-25 | $133.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $29.00K 10-Q · filed 2024-05-08 | $59.00K derived: sum of 2 quarters · filed 2025-02-25 | $105.00K derived: sum of 3 quarters · filed 2025-02-25 | $140.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $76.00K derived: sum of 2 quarters · filed 2025-02-25 | $111.00K derived: sum of 3 quarters · filed 2025-02-25 | $135.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $46.00K 10-Q · filed 2023-11-09 | $81.00K derived: sum of 2 quarters · filed 2023-11-09 | $105.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $35.00K 10-Q · filed 2023-08-10 | $59.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $23.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |